Search results for "hepatitis"

showing 10 items of 1578 documents

Trends for genetic variation of Hepatitis C Virus quasispecies in Human Immunodeficiency virus-1 coinfected patients

2007

Chronic infection by Hepatitis C Virus (HCV) causes liver fibrosis, which is accelerated by unknown mechanisms in patients with HIV-1 coinfection. The evolution of HCV quasispecies in this setting of coinfection is not fully understood. To compare HCV quasispecies between HIV-HCV coinfection and HCV monoinfection, we sequenced 340 HCV clones from the HVR-1 and NS3 regions at two different time points in two groups of treatment-naive patients with HCV-1a infection: (1) HIV-HCV positive (n=6); and (2) HIV negative-HCV positive (n=3). In HCV/HIV coinfection, we found a trend for reduced HCV genetic complexity and diversity, and a trend towards reduced dN/dS ratios in the HVR-1 region, especial…

AdultMaleCancer ResearchHepatitis C virusHepacivirusMolecular Sequence DataSequence HomologyHIV InfectionsHepacivirusViral quasispeciesViral Nonstructural Proteinsmedicine.disease_causeArticleViral ProteinsAcquired immunodeficiency syndrome (AIDS)VirologymedicineCluster AnalysisHumansPhylogenyNS3biologyGenetic Variationvirus diseasesSequence Analysis DNAHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesCD4 Lymphocyte CountChronic infectionInfectious DiseasesImmunologyCoinfectionRNA ViralVirus Research
researchProduct

HBV virological suppression: still not enough to save from hepatocellular carcinoma. A case report on a 15-year, real-life story

2017

Among HIV-infected patients worldwide, 2-4 million are chronically infected with HBV. We report a 15-year, real-life story of a patient with HBV-HIV coinfection, who developed HCC despite high treatment adherence and complete viral suppression. The aim of our report is to alert the infectious diseases community to monitor the possible development of HCC regardless of high treatment adherence and complete viral suppression.

AdultMaleCarcinoma HepatocellularCoinfectionMedicine (all)Liver NeoplasmsHIVVirological suppressionHIV InfectionsAntiviral AgentsMedication AdherenceHepatitis B ChronicHBVHumansHCCRecenti progressi in medicina
researchProduct

Lack of evidence of hepatitis in patients with oral lichen planus in China: A case control study

2016

Background: China has been one of the countries with high prevalence of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) liver disease. And lichen planus is an extrahepatic manifestation of patients with chronic HCV infection. This case-control study was conducted to investigate the relationship between oral lichen planus (OLP) and HBV/HCV infection in China. Material and Methods: A total of 776 patients, including 150 patients with OLP (Group OLP), 429 inpatients from the Trauma Ward of Oral and Maxillofacial Surgery Department (Group A), 110 patients with other oral mucosal diseases, but without a reported association with HCV infection (Group B) and 87 patients with oral liche…

AdultMaleChinamedicine.medical_specialtyHepatitis C virusOdontologíamedicine.disease_causeGastroenterologyVirusHepatitis B Antigens030207 dermatology & venereal diseases03 medical and health sciencesLiver diseaseHepatitis B Chronic0302 clinical medicinestomatognathic systemInternal medicineHumansMedicineGeneral DentistryHepatitis B virusHepatitisOral Medicine and Pathologyintegumentary systembusiness.industryResearchvirus diseases030206 dentistryHepatitis CHepatitis C AntibodiesHepatitis C ChronicMiddle AgedHepatitis B:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludVirologydigestive system diseasesstomatognathic diseasesOtorhinolaryngologyCase-Control StudiesUNESCO::CIENCIAS MÉDICASFemaleSurgeryOral lichen planusbusinessLichen Planus OralMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Predictive Scores in Primary Biliary Cirrhosis

2015

GOALS The aim of this study was to assess the long-term outcome of primary biliary cirrhosis (PBC) patients and to test the clinical value of various outcome models, such as the Mayo Risk Score (MRS), in a large single-center cohort in Germany. BACKGROUND PBC is a chronic autoimmune liver disease with a female gender predominance and a peak incidence in the fifth decade of life. PBC is characterized by portal inflammation and immune-mediated destruction of intrahepatic bile ducts in liver histology and the presence of antimitochondrial antibodies in the serum of nearly 95% of patients. In 5% to 20% of patients an overlap syndrome with autoimmune hepatitis (AIH) is diagnosed. Ursodeoxycholic…

AdultMaleCholagogues and Cholereticsmedicine.medical_specialtyPathologyAdolescentmedicine.medical_treatmentIntrahepatic bile ductsAutoimmune hepatitisLiver transplantationSeverity of Illness IndexGastroenterologyYoung AdultLiver diseasePrimary biliary cirrhosisPredictive Value of TestsInternal medicinemedicineHumansAspartate AminotransferasesChildAgedRetrospective StudiesAged 80 and overFramingham Risk ScoreLiver Cirrhosis BiliaryPlatelet Countbusiness.industryUrsodeoxycholic AcidGastroenterologyBilirubinOverlap syndromeMiddle AgedAlkaline PhosphatasePrognosismedicine.diseasedigestive system diseasesUrsodeoxycholic acidLiver TransplantationHepatitis AutoimmuneImmunoglobulin MImmunoglobulin GFemalebusinessFollow-Up Studiesmedicine.drugJournal of Clinical Gastroenterology
researchProduct

Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series

1999

No established medical therapy alters the progressive course of primary sclerosing cholangitis.To explore the potential usefulness of combined therapy with azathioprine, steroids and ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis.Case series.University hospital in Mainz, Germany.15 patients with primary sclerosing cholangitis.Azathioprine (1 to 1.5 mg/kg of body weight per day), prednisolone (1 mg/kg per day initially, tapering to 5 to 10 mg per day) and UDCA (500 to 750 mg per day).Clinical and laboratory evaluation, liver biopsy, and endoscopic retrograde cholangiography (a30% change in stenosis was considered significant).After a median observation period of 41 months (ran…

AdultMaleCholagogues and Cholereticsmedicine.medical_specialtyPrednisolonemedicine.medical_treatmentCholangitis SclerosingPilot ProjectsAzathioprineAutoimmune hepatitisGastroenterologyInflammatory bowel diseasePrimary sclerosing cholangitisInternal medicineAzathioprineInternal MedicinemedicineHumansChemotherapybusiness.industryUrsodeoxycholic AcidGeneral Medicinemedicine.diseaseUlcerative colitisUrsodeoxycholic acidSurgeryRadiographyLiverPrednisoloneDrug Therapy CombinationFemalebusinessImmunosuppressive Agentsmedicine.drugAnnals of Internal Medicine
researchProduct

Concurrent autoimmune diseases in patients with autoimmune hepatitis.

2010

Although the pathomechanisms of autoimmune diseases in various organs remain unresolved, an accumulation of autoimmune diseases in individual patients has been observed. An overlap of autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) or primary sclerosing cirrhosis has been well documented. However, the overlap of autoimmune diseases other than PBC or PSC has not yet been investigated in a large cohort.The goal of our analysis was to investigate the incidence of concurrent autoimmune diseases in patients with AIH.We analyzed our cohort of 278 patients with AIH for concurrent autoimmune diseases.A total of 111 patients (40%) were diagnosed with additional autoimmune diseases. Be…

AdultMaleCirrhosisAdolescentAutoimmune hepatitisThyroiditisAutoimmune DiseasesCohort StudiesYoung AdultPrimary biliary cirrhosisImmunopathologyMedicineHumansIn patientChildAgedAutoantibodiesHepatitisAutoimmune diseaseAged 80 and overbusiness.industryLiver Cirrhosis BiliaryGastroenterologyThyroiditis AutoimmuneMiddle Agedmedicine.diseasedigestive system diseasesHepatitis AutoimmuneImmunologyFemalebusinessFollow-Up StudiesJournal of clinical gastroenterology
researchProduct

Transforming growth factor-β1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity

1998

Abstract Background/Aims: Transforming growth factor-β 1 (TGF-β 1 ) is considered the most important mediator of hepatic fibrogenesis. At the same time, TGF-β 1 is an immunosuppressive cytokine. Development of fibrosis, often rapid, is a characteristic of autoimmune hepatitis, as is spontaneous systemic immunosuppression. The aim of our study was therefore to define the role of TGF-β 1 in autoimmune hepatitis. Methods/Results: Using the MV 1Lu bioassay, we found markedly elevated serum levels of TGF-β 1 (median 109 ng/ml) in active autoimmune hepatitis, which normalised when patients reached biochemical remission following immunosuppressive therapy (median 34 ng/ml; p =0.0001 compared to ac…

AdultMaleCirrhosisAdolescentmedicine.medical_treatmentInflammationAutoimmune hepatitismedicine.disease_causeMonocytesAutoimmunityTransforming Growth Factor betaFibrosisHumansMedicineIn Situ HybridizationAgedInflammationHepatitisHepatologybusiness.industryImmunosuppressionMiddle Agedmedicine.diseaseImmunohistochemistryHepatitis AutoimmuneCytokineLiverImmunologyBiological AssayFemalemedicine.symptombusinessBiomarkersJournal of Hepatology
researchProduct

Are hepatitis G virus and TT virus involved in cryptogenic chronic liver disease?

2002

Abstract Background . Hepatitis G virus can cause chronic infection in man but the role of this agent in chronic liver disease is poorly understood. Little is known about the relation of another newly discovered agent, the TT virus, with chronic liver disease. Aim . To investigate the rate of infection with hepatitis G virus and TT virus in patients with cryptogenic chronic liver disease. Patients . A total of 23 subjects with chronically raised alanine transaminase and a liver biopsy in whom all known causes of liver disease had been excluded, and 4D subjects with hepatitis C virus-related chronic liver disease. Methods . Evaluation of anti-hepatitis G virus by enzyme immunoassay. Hepatiti…

AdultMaleCirrhosisHepatitis Viral HumanvirusesHepatitis C virusGB virus Cmedicine.disease_causeChronic liver diseaseLiver diseasemedicineHumansHepatitis ChronicTorque teno virusHepatitis B virusHepatitisHepatologymedicine.diagnostic_testReverse Transcriptase Polymerase Chain Reactionbusiness.industryGastroenterologyAlanine TransaminaseHepatitis CFlaviviridae InfectionsMiddle Agedmedicine.diseaseVirologyDNA Virus InfectionsLiverLiver biopsyFemalebusinessDigestive and Liver Disease
researchProduct

Infectious diseases among foreign prisoners: results of a hospital-based management model in Palermo.

2017

Foreign prisoners have a high vulnerability in terms of morbidity and access to care in overcrowded Italian prisons. This paper presents and comments on the management model of infectious diseases in foreign prisoners at our outpatient clinic, in order to describe a model of management for these conditions. Overall, 133 subjects (mean age 35.5 years) from 29 countries were followed for a period of 15 years. The most commonly represented area of origin (54.1%) was the Maghreb region. HCV infection (40.6%), HIV (22.5%), HBV (9.8%) and co-infection (15%, HIV/HCV or HIV/HBV) were observed. Ten subjects had tuberculosis, and only 30% of them were compliant with the treatment. Only 46.3% of HCV m…

AdultMaleCoinfectionPrisonersHIV InfectionsHepatitis BCommunicable DiseasesHepatitis CHealth Services AccessibilityItalyRisk FactorsPrisonsPrevalenceInfectious diseasesHumansFemaleSubstance Abuse IntravenousSicilyTuberculosis PulmonaryRetrospective StudiesLe infezioni in medicina
researchProduct

Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induct…

2002

High-dose induction with alpha-interferon induces early viral clearance of hepatitis C and combined with ribavirin enhances sustained response. We assess whether adding ribavirin after viral clearance obtained by alpha-interferon induction increased the rate of viral eradication.Forty-one naïve patients with chronic hepatitis C were randomised to receive, after 4 weeks of 10 mU daily of alpha-interferon (induction), 3 mU daily for 22 weeks and 3 mU thrice weekly for 26 weeks of either interferon alone (monotherapy) or interferon plus 1000-1200 mg daily of ribavirin (combination therapy). At the end of the induction phase, 23 (56%) subjects had cleared HCV-RNA. During therapy, breakthrough w…

AdultMaleCombination therapyAdolescentHepacivirusAlpha interferonViremiaEnzyme-Linked Immunosorbent AssayHepacivirusPharmacologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialInterferonlawVirologyRibavirinHumansMedicineViremiaAgedAntiviral AgentHepatologybiologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseInfectious DiseasesTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalebusinessmedicine.drugHuman
researchProduct